Effects of cisplatin on expression of DNA ligases in MiaPaCa human pancreatic cancer cells

Biochemical and Biophysical Research Communications

Volumn 298, Issue 4, 2002, Pages 537-544

  Sun, Daekyu ^a   Urrabaz, Rheanna ^a   Buzello, Christoph ^a   Nguyen, Myhanh ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

Cisplatin; DNA ligase I; DNA repair; MiaPaCa cell

Indexed keywords

CAFFEINE; CISPLATIN; PHOSPHOTRANSFERASE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE;

ARTICLE; CANCER CELL CULTURE; CELL COUNT; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL DAMAGE; CELL DISRUPTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOSTASIS; CYTOTOXICITY; DNA REPAIR; DRUG EFFECT; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENCY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; METAPHASE; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TIME;

ANTINEOPLASTIC AGENTS; CAFFEINE; CELL CYCLE; CISPLATIN; DNA LIGASES; HUMANS; PANCREATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0036430445     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(02)02493-2     Document Type: Article

References (34)

1. E. Reed, Cisplatin, Cancer Chemother. Biol. Response Modif. 18 (1999) 144-151.
2. E.E. Trimmer, J.M. Essigmann, Cisplatin, Essays Biochem. 34 (1999) 191-211.
3. P.D. Lawley, D.H. Phillips, DNA adducts from chemotherapeutic agents, Mutat. Res. 355 (1996) 13-40.
4. P. Jordan, M. Carmo-Fonseca, Molecular mechanisms involved in cisplatin cytotoxicity, Cell Mol. Life Sci. 57 (2000) 1229-1235.
5. E. Reed, Platinum-DNA adducts, nucleotide excision repair and platinum based anti-cancer chemotherapy, Cancer Treat. Rev. 24 (1998) 331-344.
6. S.J. Araujo, F. Tirode, F. Coin, H. Pospiech, J.E. Syvaoja, M. Stucki, U. Hubscher, J.M. Egly, R.D. Wood, Nucleotide excision repair of DNA with recombinant human proteins: Definition of the minimal set of factors, active forms of TFIIH, and modulation by CAK, Genes Dev. 14 (2000) 349-359.
7. K.V. Ferry, T.C. Hamilton, S.W. Johnson, Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: Role of ERCC1-XPF, Biochem. Pharmacol. 60 (2000) 1305-1313.
8. T.R. Dunkern, G. Fritz, B. Kaina, Cisplatin-induced apoptosis in 43-3B and 27-1 cells defective in nucleotide excision repair, Mutat. Res. 486 (2001) 249-258.
9. L.R. Kelland, Preclinical perspectives on platinum resistance, Drugs 59 (Suppl. 4) (2000) 1-8, discussion 37-38.
10. M. Kartalou, J.M. Essigmann, Mechanisms of resistance to cisplatin, Mutat. Res. 478 (2001) 23-43.
11. A.E. Tomkinson, J. Chen, J. Besterman, I. Husain, Cellular functions of mammalian DNA ligases, in: J.A. Nickoloff, M.F. Hoekstra (Eds.), DNA Damage and Repair Vol II: DNA Repair in Higher Eukaryotes, Humana Press, Totowa, NJ, 1998, pp. 181-198.
12. S. Soderhall, T. Lindahl, Mammalian DNA ligases, serological evidence for two separate enzymes, J. Biol. Chem. 250 (1975) 8438-8444.
13. J. Chen, A.E. Tomkinson, W. Ramos, Z.B. Mackey, S. Danehower, C.A. Walter, R.A. Schultz, J.M. Besterman, I. Husain, Mammalian DNA ligase III: Molecular cloning, chromosomal localization, and expression in spermatocytes undergoing meiotic recombination, Mol. Cell. Biol. 15 (1995) 5412-5422.
14. U. Grawunder, D. Zimmer, S. Fugmann, K. Schwarz, M.R. Lieber, DNA ligase IV is essential for V(D)J recombination and DNA double-stranded break repair in human precursor lymphocytes, Mol. Cell. 2 (1998) 477-484.
15. C. Prigent, M.S. Satoh, G. Daly, D.E. Barnes, T. Lindahl, Aberrant DNA repair and DNA replication due to an inherited enzymatic defect in human DNA ligase I, Mol. Cell. Biol. 14 (1994) 310-317.
16. S. Nocentini, Rejoining kinetics of DNA single- and double-strand breaks in normal and DNA ligase-deficient cells after exposure to ultraviolet C and gamma radiation: An evaluation of ligating activities involved in different DNA repair processes, Radiat. Res. 151 (1999) 423-432.
17. D. Sun, L.H. Hurley, D.D. Von Hoff, Telomerase assay using biotinylated-primer extension and magnetic separation of the products, BioTechniques 25 (1998) 1046-1051.
18. Y. Shiloh, ATM and ATR: Networking cellular response to DNA damage, Curr. Opin. Genet. Dev. 11 (2001) 71-77.
19. H. Zhao, H. Piwnica-Worms, ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1, Mol. Cell. Biol. 21 (2001) 4129-4239.
20. C. Feijoo, C. Hall-Jackson, R. Wu, D. Jenkins, J. Leitch, D.M. Gilbert, C. Smythe, Activation of mammalian Chk1 during DNA replication arrest: A role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing, J. Cell Biol. 154 (2001) 913-923.
21. N.J. Sarkaria, E.C. Busby, R.S. Tibbetts, P. Roos, Y. Taya, L.M. Karnitz, R.T. Abraham, Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine, Cancer Res. 59 (1999) 4375-4382.
22. N. Guo, D.V. Faller, C. Vaziri, Carcinogen-induced S-phase arrest is Chk1 mediated and caffeine sensitive, Cell Growth Diff. 13 (2002) 77-86.
23. S. Soderhall, DNA ligases during rat liver regeneration, Nature 260 (1976) 640-642.
24. A. Montecucco, G. Biamonti, E. Savini, F. Focher, S. Spadari, G. Ciarrocchi, DNA ligase I gene expression during differentiation and cell proliferation, Nucleic Acids Res. 20 (1992) 6209-6214.
25. H. Teraoka, M. Sawai, K. Yamamoto, K. Tsukada, DNA ligase I mRNA and enzyme levels in human hematopoietic cells under dimethyl sulfoxide-induced growth-arrest and differentiation, Biochem. Int. 26 (1992) 963-971.
26. R. Silvestrini, O. Sanfilippo, M.G. Daidone, N. Zaffaroni, Inhibition of DNA synthesis in selection of anticancer therapy, Prog. Clin. Biol. Res. 276 (1988) 93-103.
27. K. Kawabata, Y. Nio, M. Imamura, M. Fukumoto, Anticancer chemosensitivity and growth rate of freshly separated human colorectal cancer cells assessed by in vitro DNA synthesis inhibition assay, Anticancer Res. 189 (1998) 1633-1640.
28. R. Rossi, A. Villa, C. Negri, I. Scovassi, G. Ciarrocchi, G. Biamonti, A. Montecucco, The replication factory targeting sequence/PCNA-binding site is required in G(1) to control the phosphorylation status of DNA ligase I, EMBO J. 18 (1999) 5745-5754.
29. D. Sun, R. Urrabaz, S. Kelly, M. Nguyen, S. Weitman, Enhancement of DNA ligase I levels by gemcitabine in human cancer cells, Clin. Cancer Res. 8 (2002) 1189-1195.
30. R.T. Abraham, Cell cycle checkpoint signaling through the ATM and ATR kinases, Genes Dev. 159 (2001) 2177-2196.
31. D.E. Barnes, A.E. Tomkinson, A.R. Lehmann, A.D.B. Webster, T. Lindahl, Mutations in the DNA ligase I gene of an individual with immunodeficiencies and cellular hypersensitivity to DNA-damaging agents, Cell 69 (1992) 495-503.
32. B.T. Hill, K.J. Scanlon, J. Hansson, A. Harstrick, M. Pera, A.M. Fichtinger-Schepman, S.A. Shellard, Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients, Eur. J. Cancer 30A (1994) 832-837.
33. V.V. Levenson, I.A. Davidovich, I.B. Roninson, Pleiotropic resistance to DNA-interactive drugs is associated with increased expression of genes involved in DNA replication, repair, and stress response, Cancer Res. 60 (2000) 5027-5030.
34. Q. Li, J.J. Yu, C. Mu, M.K. Yunmbam, D. Slavsky, C.L. Cross, F. Bostick-Bruton, E. Reed, Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells, Anticancer Res. 20 (2000) 645-652.